Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma

Share :
Published: 10 Dec 2019
Views: 941
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

Dr Saad Usmani speaks at the 2019 ASH meeting about the results from the CANDOR study which examined the combination of daratumumab, carfilzomib and dexamethasone for the treatment of patients with relapse/refractory multiple myeloma (MM).

He explains that this drug combination significantly increased survival for this patient population.

Watch our interview with Dr Usmani here

Read more about the study here.